Raffaella Casolino
University of Glasgow
GermlineCancerInternal medicineSomatic cellOncologyVirologyPrecision medicineIntensive care medicineImmunotherapyTherapeutic approachAgonistDiseaseMEDLINEPancreatic cancerAdenocarcinomaHomologous Recombination DeficiencyTreatment responsePancreatic ductal adenocarcinomaMolecular heterogeneity2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)In patientEffective treatmentTh2 cytokinesPredictive biomarkerPreoperative treatmentCancer researchDNA sequencingClinical trialDrug developmentText miningMedicineSubtypingPath (graph theory)PandemicMeta-analysis
5Publications
2H-index
5Citations
Publications 7
Newest
#1Raffaella Casolino (Glas.: University of Glasgow)H-Index: 2
#2Andrew V. Biankin (Glas.: University of Glasgow)H-Index: 73
Last. David K. Chang (Glas.: University of Glasgow)H-Index: 48
view all 19 authors...
Source
#1Raffaella Casolino (Glas.: University of Glasgow)H-Index: 2
#2Andrew V. Biankin (Glasgow Royal Infirmary)H-Index: 73
Source
#1Raffaella Casolino (Glas.: University of Glasgow)H-Index: 2
#2Salvatore PaiellaH-Index: 23
Last. Fieke E.M. Froeling (Glas.: University of Glasgow)H-Index: 15
view all 18 authors...
PURPOSETo analyze the prevalence of homologous recombination deficiency (HRD) in patients with pancreatic ductal adenocarcinoma (PDAC).MATERIALS AND METHODSWe conducted a systematic review and meta...
Source
#1Raffaella Casolino (Glas.: University of Glasgow)H-Index: 2
#2Chiara Braconi (Beatson West of Scotland Cancer Centre)H-Index: 28
Source
#1Raffaella Casolino (Glas.: University of Glasgow)H-Index: 2
#2Chiara Braconi (Glas.: University of Glasgow)H-Index: 28
Last. Talia Golan (Sheba Medical Center)H-Index: 20
view all 11 authors...
This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalized therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of "all-comer" treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly im...
4 CitationsSource
#1Fieke E.M. Froeling (Glas.: University of Glasgow)H-Index: 6
#1Fieke E.M. Froeling (Glas.: University of Glasgow)H-Index: 15
Last. David K. Chang (Glas.: University of Glasgow)H-Index: 48
view all 5 authors...
Substantial progress in recent years has dramatically increased our knowledge of the molecular basis of cancer, revealing new potential therapeutic targets and paving the way for effective personalised medicine for the treatment of many tumour types. However, pancreatic cancer has been lagging behind in this success and continues to be one of the most lethal solid malignancies. Its molecular heterogeneity and the unselected design of the majority of clinical trials to date can in part explain th...
3 CitationsSource
#1Davide MelisiH-Index: 31
#2Geny PiroH-Index: 17
Last. Giampaolo TortoraH-Index: 83
view all 15 authors...
Source